Comparative membrane proteomics

A technical advancement in the search of renal cell carcinoma biomarkers

Francesca Raimondo, Samuele Corbetta, Andrea Savoia, Clizia Chinello, Marta Cazzaniga, Francesco Rocco, Silvano Bosari, Marco Grasso, Giorgio Bovo, Fulvio Magni, Marina Pitto

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Renal Cell Carcinoma (RCC) is the most common kidney cancer, accounting for 3% of adult malignancies, with high metastatic potential and radio-/chemo-resistance. To investigate the protein profile of membrane microdomains (MD), plasma membrane supramolecular structures involved in cell signaling, transport, and neoplastic transformation, we set up a proteomic bottom-up approach as a starting point for the identification of potential RCC biomarkers. We purified MD from RCC and adjacent normal kidney (ANK) tissues, through their resistance to non-ionic detergents followed by ultracentrifugation in sucrose density gradient. MD from 5 RCC/ANK tissues were then pooled and analysed by LC-ESI-MS/MS. In order to identify the highest number of proteins and increase the amount of membrane and hydrophobic ones, we first optimized an enzymatic digestion protocol based on Filter Aided Sample Preparation (FASP), coupled to MD delipidation. The MS analysis led to the identification of 742 ANK MD and 721 RCC MD proteins, of which, respectively, 53.1% and 52.6% were membrane- bound. Additionally, we evaluated RCC MD differential proteome by label-free quantification; 170 and 126 proteins were found to be, respectively, up-regulated and down-regulated in RCC MD. Some differential proteins, namely CA2, CD13, and ANXA2, were subjected to validation by immunodecoration. These results show the importance of setting up different protocols for the proteomic analysis of membrane proteins, specific to the different molecular features of the samples. Furthermore, the subcellular proteomic approach provided a list of differentially expressed proteins among which RCC biomarkers may be looked for.

Original languageEnglish
Pages (from-to)1708-1716
Number of pages9
JournalMolecular BioSystems
Volume11
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Renal Cell Carcinoma
Proteomics
Biomarkers
Membranes
Proteins
Kidney
Membrane Microdomains
Kidney Neoplasms
Ultracentrifugation
Proteome
Radio
Detergents
Sucrose
Digestion
Membrane Proteins
Cell Membrane
Neoplasms

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Biology

Cite this

Raimondo, F., Corbetta, S., Savoia, A., Chinello, C., Cazzaniga, M., Rocco, F., ... Pitto, M. (2015). Comparative membrane proteomics: A technical advancement in the search of renal cell carcinoma biomarkers. Molecular BioSystems, 11(6), 1708-1716. https://doi.org/10.1039/c5mb00020c

Comparative membrane proteomics : A technical advancement in the search of renal cell carcinoma biomarkers. / Raimondo, Francesca; Corbetta, Samuele; Savoia, Andrea; Chinello, Clizia; Cazzaniga, Marta; Rocco, Francesco; Bosari, Silvano; Grasso, Marco; Bovo, Giorgio; Magni, Fulvio; Pitto, Marina.

In: Molecular BioSystems, Vol. 11, No. 6, 01.06.2015, p. 1708-1716.

Research output: Contribution to journalArticle

Raimondo, F, Corbetta, S, Savoia, A, Chinello, C, Cazzaniga, M, Rocco, F, Bosari, S, Grasso, M, Bovo, G, Magni, F & Pitto, M 2015, 'Comparative membrane proteomics: A technical advancement in the search of renal cell carcinoma biomarkers', Molecular BioSystems, vol. 11, no. 6, pp. 1708-1716. https://doi.org/10.1039/c5mb00020c
Raimondo F, Corbetta S, Savoia A, Chinello C, Cazzaniga M, Rocco F et al. Comparative membrane proteomics: A technical advancement in the search of renal cell carcinoma biomarkers. Molecular BioSystems. 2015 Jun 1;11(6):1708-1716. https://doi.org/10.1039/c5mb00020c
Raimondo, Francesca ; Corbetta, Samuele ; Savoia, Andrea ; Chinello, Clizia ; Cazzaniga, Marta ; Rocco, Francesco ; Bosari, Silvano ; Grasso, Marco ; Bovo, Giorgio ; Magni, Fulvio ; Pitto, Marina. / Comparative membrane proteomics : A technical advancement in the search of renal cell carcinoma biomarkers. In: Molecular BioSystems. 2015 ; Vol. 11, No. 6. pp. 1708-1716.
@article{b05f4c4b6d5f47648fa6862e72ae6e7e,
title = "Comparative membrane proteomics: A technical advancement in the search of renal cell carcinoma biomarkers",
abstract = "Renal Cell Carcinoma (RCC) is the most common kidney cancer, accounting for 3{\%} of adult malignancies, with high metastatic potential and radio-/chemo-resistance. To investigate the protein profile of membrane microdomains (MD), plasma membrane supramolecular structures involved in cell signaling, transport, and neoplastic transformation, we set up a proteomic bottom-up approach as a starting point for the identification of potential RCC biomarkers. We purified MD from RCC and adjacent normal kidney (ANK) tissues, through their resistance to non-ionic detergents followed by ultracentrifugation in sucrose density gradient. MD from 5 RCC/ANK tissues were then pooled and analysed by LC-ESI-MS/MS. In order to identify the highest number of proteins and increase the amount of membrane and hydrophobic ones, we first optimized an enzymatic digestion protocol based on Filter Aided Sample Preparation (FASP), coupled to MD delipidation. The MS analysis led to the identification of 742 ANK MD and 721 RCC MD proteins, of which, respectively, 53.1{\%} and 52.6{\%} were membrane- bound. Additionally, we evaluated RCC MD differential proteome by label-free quantification; 170 and 126 proteins were found to be, respectively, up-regulated and down-regulated in RCC MD. Some differential proteins, namely CA2, CD13, and ANXA2, were subjected to validation by immunodecoration. These results show the importance of setting up different protocols for the proteomic analysis of membrane proteins, specific to the different molecular features of the samples. Furthermore, the subcellular proteomic approach provided a list of differentially expressed proteins among which RCC biomarkers may be looked for.",
author = "Francesca Raimondo and Samuele Corbetta and Andrea Savoia and Clizia Chinello and Marta Cazzaniga and Francesco Rocco and Silvano Bosari and Marco Grasso and Giorgio Bovo and Fulvio Magni and Marina Pitto",
year = "2015",
month = "6",
day = "1",
doi = "10.1039/c5mb00020c",
language = "English",
volume = "11",
pages = "1708--1716",
journal = "Molecular BioSystems",
issn = "1742-206X",
publisher = "Royal Society of Chemistry",
number = "6",

}

TY - JOUR

T1 - Comparative membrane proteomics

T2 - A technical advancement in the search of renal cell carcinoma biomarkers

AU - Raimondo, Francesca

AU - Corbetta, Samuele

AU - Savoia, Andrea

AU - Chinello, Clizia

AU - Cazzaniga, Marta

AU - Rocco, Francesco

AU - Bosari, Silvano

AU - Grasso, Marco

AU - Bovo, Giorgio

AU - Magni, Fulvio

AU - Pitto, Marina

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Renal Cell Carcinoma (RCC) is the most common kidney cancer, accounting for 3% of adult malignancies, with high metastatic potential and radio-/chemo-resistance. To investigate the protein profile of membrane microdomains (MD), plasma membrane supramolecular structures involved in cell signaling, transport, and neoplastic transformation, we set up a proteomic bottom-up approach as a starting point for the identification of potential RCC biomarkers. We purified MD from RCC and adjacent normal kidney (ANK) tissues, through their resistance to non-ionic detergents followed by ultracentrifugation in sucrose density gradient. MD from 5 RCC/ANK tissues were then pooled and analysed by LC-ESI-MS/MS. In order to identify the highest number of proteins and increase the amount of membrane and hydrophobic ones, we first optimized an enzymatic digestion protocol based on Filter Aided Sample Preparation (FASP), coupled to MD delipidation. The MS analysis led to the identification of 742 ANK MD and 721 RCC MD proteins, of which, respectively, 53.1% and 52.6% were membrane- bound. Additionally, we evaluated RCC MD differential proteome by label-free quantification; 170 and 126 proteins were found to be, respectively, up-regulated and down-regulated in RCC MD. Some differential proteins, namely CA2, CD13, and ANXA2, were subjected to validation by immunodecoration. These results show the importance of setting up different protocols for the proteomic analysis of membrane proteins, specific to the different molecular features of the samples. Furthermore, the subcellular proteomic approach provided a list of differentially expressed proteins among which RCC biomarkers may be looked for.

AB - Renal Cell Carcinoma (RCC) is the most common kidney cancer, accounting for 3% of adult malignancies, with high metastatic potential and radio-/chemo-resistance. To investigate the protein profile of membrane microdomains (MD), plasma membrane supramolecular structures involved in cell signaling, transport, and neoplastic transformation, we set up a proteomic bottom-up approach as a starting point for the identification of potential RCC biomarkers. We purified MD from RCC and adjacent normal kidney (ANK) tissues, through their resistance to non-ionic detergents followed by ultracentrifugation in sucrose density gradient. MD from 5 RCC/ANK tissues were then pooled and analysed by LC-ESI-MS/MS. In order to identify the highest number of proteins and increase the amount of membrane and hydrophobic ones, we first optimized an enzymatic digestion protocol based on Filter Aided Sample Preparation (FASP), coupled to MD delipidation. The MS analysis led to the identification of 742 ANK MD and 721 RCC MD proteins, of which, respectively, 53.1% and 52.6% were membrane- bound. Additionally, we evaluated RCC MD differential proteome by label-free quantification; 170 and 126 proteins were found to be, respectively, up-regulated and down-regulated in RCC MD. Some differential proteins, namely CA2, CD13, and ANXA2, were subjected to validation by immunodecoration. These results show the importance of setting up different protocols for the proteomic analysis of membrane proteins, specific to the different molecular features of the samples. Furthermore, the subcellular proteomic approach provided a list of differentially expressed proteins among which RCC biomarkers may be looked for.

UR - http://www.scopus.com/inward/record.url?scp=84934874312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934874312&partnerID=8YFLogxK

U2 - 10.1039/c5mb00020c

DO - 10.1039/c5mb00020c

M3 - Article

VL - 11

SP - 1708

EP - 1716

JO - Molecular BioSystems

JF - Molecular BioSystems

SN - 1742-206X

IS - 6

ER -